The North America Veterinary Antimicrobial Susceptibility Testing Market was valued at USD 296 Million in 2025 and is expected to reach USD 664 Million by 2035, growing at a CAGR of 7.7% from 2024 to 2035.
The economic impact of tariffs on "North America Veterinary Antimicrobial Susceptibility Testing Market".
Market Growth Drivers
Increasing prevalence of zoonotic diseases: The rise in zoonotic infectious diseases in animals and the associated risks to human health are driving demand for advanced antimicrobial susceptibility testing in the veterinary sector. Companies like Thermo Fisher Scientific have reported higher sales and increased investments in veterinary diagnostics in response to these public health concerns, supporting widespread adoption of susceptibility testing solutions.
Stringent regulatory guidelines: The implementation of strict government regulations regarding the usage of antibiotics in food-producing animals has compelled veterinary clinics and diagnostic laboratories to invest in antimicrobial susceptibility testing. For instance, IDEXX Laboratories has advanced its product offerings to ensure compliance with updated FDA and USDA guidelines, thus strengthening its position and fueling market growth.
Key Market Trends
Integration of automation and AI in lab workflows: Veterinary diagnostic laboratories are increasingly leveraging automation and artificial intelligence to enhance the efficiency and accuracy of susceptibility testing. BD (Becton, Dickinson and Company) launched automated platforms incorporating AI-driven data analysis that reduces processing times and delivers more reliable results.
Expansion of companion animal diagnostics: With a growing pet population in North America, there is a significant uptick in demand for companion animal antimicrobial susceptibility testing. Zoetis, for example, has introduced specialized panels and software tools tailored for rapid identification of resistant pathogens in pets, reflecting the growing trend toward pet healthcare and diagnostics.
Market Opportunities
Emerging rapid test technologies: The market is seeing an opportunity in the development and adoption of rapid, point-of-care antimicrobial susceptibility testing kits. Companies like Heska Corporation are investing in portable diagnostic devices aimed at veterinary clinics, allowing on-site testing and faster clinical decision-making.
Collaborative research initiatives: Opportunities exist for industry players to partner with academic and government institutions to develop standardized testing protocols and new antibiotic alternatives, expanding the scope of the veterinary antimicrobial susceptibility testing market.
North America Veterinary Antimicrobial Susceptibility Testing Market Revenue (USD Million), 2020-2035
The market revenue chart indicates a steady upward trajectory from 2020 to 2035. In 2020, the market was valued at USD 194 Million, climbing to USD 296 Million by 2025. The trend continues robustly, reflecting the region’s increasing focus on veterinary diagnostics—reaching USD 664 Million in 2035. The data highlight key inflection points aligning with regulatory changes and adoption of novel diagnostic technologies, supporting sustained growth throughout the period.
North America Veterinary Antimicrobial Susceptibility Testing Market Share by Region, 2025
In 2025, the United States dominates the North American market for veterinary antimicrobial susceptibility testing, holding a 67% share due to its advanced veterinary healthcare infrastructure and strong regulatory framework. Canada accounts for 22% of the market, while Mexico follows with 7%. Other regions, including Puerto Rico and other North American territories, hold minor shares, at 2% each. The dominance of the U.S. underscores its leadership in the adoption and development of veterinary diagnostic technologies.
Recent Developments in the Market
In March 2024, Thermo Fisher Scientific launched an upgraded version of its Sensititre system in North America, optimized for veterinary use. The updated platform features automation capabilities and increased panel throughput, which allow veterinary diagnostic labs to reduce turnaround time for susceptibility results.
In May 2024, IDEXX Laboratories announced a partnership with a leading animal health research institute to co-develop new susceptibility testing protocols. This collaboration aims to set industry benchmarks for antimicrobial stewardship in both companion and food-producing animal sectors, reinforcing IDEXX’s innovation leadership.
In June 2024, Zoetis completed the acquisition of a diagnostic device startup specializing in rapid antimicrobial resistance testing. This strategic move is expected to expedite Zoetis’s pipeline development and expand its presence in the growing rapid diagnostics market, responding to the rising need for fast and precise veterinary antibiotic stewardship solutions.
Press Releases